Graft-versus-host disease: How to translate new insights into new therapeutic strategies

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Graft-versus-host disease occurs when transplanted donor-derived T lymphocytes recognize major or minor histocompatibility complex proteins and their associated peptides expressed by recipient antigen-presenting cells. A widely accepted paradigm for the pathophysiology of acute GVHD is based on the existence of 3 sequential steps: (1) injury to the host environment (as would occur during conditioning regimens); (2) donor T-cell activation, proliferation, and differentiation; and (3) damage to the target tissue caused by either cytotoxicity or indirectly by inflammatory cytokines. In order to reduce the incidence of GVHD, recent studies have focused on methods of prophylaxis as well as novel treatments for established GVHD. We review each phase in the development of acute GVHD and discuss recently developed interventions aimed to prevent or treat GVHD by interfering with these pathways.

Original languageEnglish (US)
Pages (from-to)815-825
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2004

Fingerprint

Graft vs Host Disease
T-Lymphocytes
Antigen-Presenting Cells
Major Histocompatibility Complex
Cell Differentiation
Cell Proliferation
Cytokines
Peptides
Incidence
Wounds and Injuries
Therapeutics
Proteins

Keywords

  • ATG
  • Alemtuzumab
  • Extracorporeal photophoresis
  • Graft-versus-host disease
  • MMR
  • Pento-statin
  • Sirolimus
  • Stem cell transplant
  • T cell depletion

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{58cbb26b5abc4294a674de9379fb564a,
title = "Graft-versus-host disease: How to translate new insights into new therapeutic strategies",
abstract = "Graft-versus-host disease occurs when transplanted donor-derived T lymphocytes recognize major or minor histocompatibility complex proteins and their associated peptides expressed by recipient antigen-presenting cells. A widely accepted paradigm for the pathophysiology of acute GVHD is based on the existence of 3 sequential steps: (1) injury to the host environment (as would occur during conditioning regimens); (2) donor T-cell activation, proliferation, and differentiation; and (3) damage to the target tissue caused by either cytotoxicity or indirectly by inflammatory cytokines. In order to reduce the incidence of GVHD, recent studies have focused on methods of prophylaxis as well as novel treatments for established GVHD. We review each phase in the development of acute GVHD and discuss recently developed interventions aimed to prevent or treat GVHD by interfering with these pathways.",
keywords = "ATG, Alemtuzumab, Extracorporeal photophoresis, Graft-versus-host disease, MMR, Pento-statin, Sirolimus, Stem cell transplant, T cell depletion",
author = "DeVetten, {Marcel P} and Vose, {Julie Marie}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2004.10.005",
language = "English (US)",
volume = "10",
pages = "815--825",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Graft-versus-host disease

T2 - How to translate new insights into new therapeutic strategies

AU - DeVetten, Marcel P

AU - Vose, Julie Marie

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Graft-versus-host disease occurs when transplanted donor-derived T lymphocytes recognize major or minor histocompatibility complex proteins and their associated peptides expressed by recipient antigen-presenting cells. A widely accepted paradigm for the pathophysiology of acute GVHD is based on the existence of 3 sequential steps: (1) injury to the host environment (as would occur during conditioning regimens); (2) donor T-cell activation, proliferation, and differentiation; and (3) damage to the target tissue caused by either cytotoxicity or indirectly by inflammatory cytokines. In order to reduce the incidence of GVHD, recent studies have focused on methods of prophylaxis as well as novel treatments for established GVHD. We review each phase in the development of acute GVHD and discuss recently developed interventions aimed to prevent or treat GVHD by interfering with these pathways.

AB - Graft-versus-host disease occurs when transplanted donor-derived T lymphocytes recognize major or minor histocompatibility complex proteins and their associated peptides expressed by recipient antigen-presenting cells. A widely accepted paradigm for the pathophysiology of acute GVHD is based on the existence of 3 sequential steps: (1) injury to the host environment (as would occur during conditioning regimens); (2) donor T-cell activation, proliferation, and differentiation; and (3) damage to the target tissue caused by either cytotoxicity or indirectly by inflammatory cytokines. In order to reduce the incidence of GVHD, recent studies have focused on methods of prophylaxis as well as novel treatments for established GVHD. We review each phase in the development of acute GVHD and discuss recently developed interventions aimed to prevent or treat GVHD by interfering with these pathways.

KW - ATG

KW - Alemtuzumab

KW - Extracorporeal photophoresis

KW - Graft-versus-host disease

KW - MMR

KW - Pento-statin

KW - Sirolimus

KW - Stem cell transplant

KW - T cell depletion

UR - http://www.scopus.com/inward/record.url?scp=10344252879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344252879&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2004.10.005

DO - 10.1016/j.bbmt.2004.10.005

M3 - Review article

C2 - 15570250

AN - SCOPUS:10344252879

VL - 10

SP - 815

EP - 825

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -